These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 23950208)

  • 1. Cetuximab attenuates its cytotoxic and radiosensitizing potential by inducing fibronectin biosynthesis.
    Eke I; Storch K; Krause M; Cordes N
    Cancer Res; 2013 Oct; 73(19):5869-79. PubMed ID: 23950208
    [TBL] [Abstract][Full Text] [Related]  

  • 2. p38 MAPK-induced MDM2 degradation confers paclitaxel resistance through p53-mediated regulation of EGFR in human lung cancer cells.
    Park SH; Seong MA; Lee HY
    Oncotarget; 2016 Feb; 7(7):8184-99. PubMed ID: 26799187
    [TBL] [Abstract][Full Text] [Related]  

  • 3. EGFR/JIP-4/JNK2 signaling attenuates cetuximab-mediated radiosensitization of squamous cell carcinoma cells.
    Eke I; Schneider L; Förster C; Zips D; Kunz-Schughart LA; Cordes N
    Cancer Res; 2013 Jan; 73(1):297-306. PubMed ID: 23074283
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor.
    Huang S; Armstrong EA; Benavente S; Chinnaiyan P; Harari PM
    Cancer Res; 2004 Aug; 64(15):5355-62. PubMed ID: 15289342
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Galectin-1 promotes lung cancer progression and chemoresistance by upregulating p38 MAPK, ERK, and cyclooxygenase-2.
    Chung LY; Tang SJ; Sun GH; Chou TY; Yeh TS; Yu SL; Sun KH
    Clin Cancer Res; 2012 Aug; 18(15):4037-47. PubMed ID: 22696230
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting.
    Matar P; Rojo F; Cassia R; Moreno-Bueno G; Di Cosimo S; Tabernero J; Guzmán M; Rodriguez S; Arribas J; Palacios J; Baselga J
    Clin Cancer Res; 2004 Oct; 10(19):6487-501. PubMed ID: 15475436
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MicroRNA-133b inhibits the growth of non-small-cell lung cancer by targeting the epidermal growth factor receptor.
    Liu L; Shao X; Gao W; Zhang Z; Liu P; Wang R; Huang P; Yin Y; Shu Y
    FEBS J; 2012 Oct; 279(20):3800-12. PubMed ID: 22883469
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The role of Smad4 and MAPK proteins in signal transduction pathway in non-small cell lung cancer].
    Tong XD; Liu HX; Zhao HR; Xu SG; Li Y; Han LB; Zhang L
    Zhonghua Zhong Liu Za Zhi; 2006 Oct; 28(10):741-5. PubMed ID: 17366784
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Notch-1 contributes to epidermal growth factor receptor tyrosine kinase inhibitor acquired resistance in non-small cell lung cancer in vitro and in vivo.
    Xie M; He CS; Wei SH; Zhang L
    Eur J Cancer; 2013 Nov; 49(16):3559-72. PubMed ID: 23916913
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epidermal growth factor competes with EGF receptor inhibitors to induce cell death in EGFR-overexpressing tumor cells.
    Song JY; Lee SW; Hong JP; Chang SE; Choe H; Choi J
    Cancer Lett; 2009 Oct; 283(2):135-42. PubMed ID: 19380191
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhanced cytotoxic activity of cetuximab in EGFR-positive lung cancer by conjugating with gold nanoparticles.
    Qian Y; Qiu M; Wu Q; Tian Y; Zhang Y; Gu N; Li S; Xu L; Yin R
    Sci Rep; 2014 Dec; 4():7490. PubMed ID: 25502402
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mechanisms of enhanced radiation response following epidermal growth factor receptor signaling inhibition by erlotinib (Tarceva).
    Chinnaiyan P; Huang S; Vallabhaneni G; Armstrong E; Varambally S; Tomlins SA; Chinnaiyan AM; Harari PM
    Cancer Res; 2005 Apr; 65(8):3328-35. PubMed ID: 15833866
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of EGFR pathway signaling and the metastatic potential of breast cancer cells by PA-MSHA mediated by type 1 fimbriae via a mannose-dependent manner.
    Liu ZB; Hou YF; Zhu J; Hu DL; Jin W; Ou ZL; Di GH; Wu J; Shen ZZ; Shao ZM
    Oncogene; 2010 May; 29(20):2996-3009. PubMed ID: 20228837
    [TBL] [Abstract][Full Text] [Related]  

  • 14. RNAi-mediated silencing of VEGF-C inhibits non-small cell lung cancer progression by simultaneously down-regulating the CXCR4, CCR7, VEGFR-2 and VEGFR-3-dependent axes-induced ERK, p38 and AKT signalling pathways.
    Feng Y; Hu J; Ma J; Feng K; Zhang X; Yang S; Wang W; Zhang J; Zhang Y
    Eur J Cancer; 2011 Oct; 47(15):2353-63. PubMed ID: 21680174
    [TBL] [Abstract][Full Text] [Related]  

  • 15. p190A RhoGAP is involved in EGFR pathways and promotes proliferation, invasion and migration in lung adenocarcinoma cells.
    Notsuda H; Sakurada A; Endo C; Okada Y; Horii A; Shima H; Kondo T
    Int J Oncol; 2013 Nov; 43(5):1569-77. PubMed ID: 24043274
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Down-regulation of MSH2 expression by an Hsp90 inhibitor enhances pemetrexed-induced cytotoxicity in human non-small-cell lung cancer cells.
    Tung CL; Chiu HC; Jian YJ; Jian YT; Chen CY; Syu JJ; Wo TY; Huang YJ; Tseng SC; Lin YW
    Exp Cell Res; 2014 Apr; 322(2):345-54. PubMed ID: 24530475
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Irradiation and various cytotoxic drugs enhance tyrosine phosphorylation and beta(1)-integrin clustering in human A549 lung cancer cells in a substratum-dependent manner in vitro.
    Cordes N; Beinke C; Plasswilm L; van Beuningen D
    Strahlenther Onkol; 2004 Mar; 180(3):157-64. PubMed ID: 14991204
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antiapoptotic activity of autocrine interleukin-22 and therapeutic effects of interleukin-22-small interfering RNA on human lung cancer xenografts.
    Zhang W; Chen Y; Wei H; Zheng C; Sun R; Zhang J; Tian Z
    Clin Cancer Res; 2008 Oct; 14(20):6432-9. PubMed ID: 18927282
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nicotine stimulates human lung cancer cell growth by inducing fibronectin expression.
    Zheng Y; Ritzenthaler JD; Roman J; Han S
    Am J Respir Cell Mol Biol; 2007 Dec; 37(6):681-90. PubMed ID: 17600315
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination therapy with VEGFR2 and EGFR siRNA enhances the antitumor effect of cisplatin in non-small cell lung cancer xenografts.
    Chen S; Liu X; Gong W; Yang H; Luo D; Zuo X; Li W; Wu P; Liu L; Xu Q; Ji A
    Oncol Rep; 2013 Jan; 29(1):260-8. PubMed ID: 23117577
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.